8-K filing — Keros Therapeutics, Inc. (KROS)
Filed: 2026-09-08 AccNo: 0001664710-26-000053 Size: 164 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Keros Therapeutics Reveals $5M Share Repurchase Authorization
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.
Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of $(0.76) per share